• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical & developmental immunology. >T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology
【24h】

T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology

机译：T细胞和过继免疫疗法：胃肠道肿瘤学的最新发展和未来前景。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gastrointestinal oncology is one of the foremost causes of death: the gastric cancer accounts for 10.4% of cancer deaths worldwide, the pancreatic cancer for 6%, and finally, the colorectal cancer for 9% of all cancer-related deaths. For all these gastrointestinal cancers, surgical tumor resection remains the primary curative treatment, but the overall 5-year survival rate remains poor, ranging between 20–25%; the addition of combined modality strategies (pre- or postoperative chemoradiotherapy or perioperative chemotherapy) results in 5-year survival rates of only 30–35%. Therefore, many investigators believe that the potential for making significant progress lies on understanding and exploiting the molecular biology of gastrointestinal tumors to investigate new therapeutic strategies such as specific immunotherapy. In this paper we will focus on recent knowledge concerning the role of T cells and the use of T adoptive immunotherapy in the treatment of gastrointestinal cancers.
机译：胃肠道肿瘤是最主要的死亡原因之一：胃癌占全世界癌症死亡的10.4％，胰腺癌占6％，最后，结直肠癌占所有癌症相关死亡的9％。对于所有这些胃肠道癌，外科手术切除仍是主要的治疗方法，但总体5年生存率仍然很差，在20％至25％之间。联合方式治疗（术前或术后放化疗或围手术期化疗）的联合使用可使5年生存率仅为30％至35％。因此，许多研究者认为，取得重大进展的潜力在于了解和利用胃肠道肿瘤的分子生物学来研究诸如特异性免疫疗法等新的治疗策略。在本文中，我们将重点关注有关T细胞的作用以及T过继免疫疗法在胃肠道癌症治疗中的应用的最新知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号